Viridian Therapeutics (VRDN) is in focus after reporting a larger than expected Q4 2025 loss and lower than forecast revenue. Its lead thyroid eye disease candidate remains under FDA Priority Review and EMA review.

At a share price of US$30.25, Viridian’s 1 day share price return of 2.96% and 7 day share price return of 7.77% follow a weaker 30 day share price return of an 8.33% decline. The 1 year total shareholder return of 109.92% contrasts with a 3 year total shareholder return of a 7.35% decline, suggesting strong recent momentum after a more mixed multi year experience.

If this kind of earnings driven move has your attention, it might be a good time to see what else is moving in health related biotech and check out 28 healthcare AI stocks as a starting list.

With Viridian reporting a larger Q4 loss, meaningful full-year revenue, and trading about 38% below the average analyst price target, the key question now is whether investors are looking at an undervalued biotech or a market that already reflects future growth.

Preferred Price-to-Sales of 43.6x: Is It Justified?

Viridian is trading on a P/S of 43.6x, while the last close sits at $30.25, and that valuation stands out sharply against both peers and the broader US Biotechs industry.

The P/S ratio compares the company’s market value to its revenue. It can be a common reference point for early stage or loss making biotech names where earnings are not yet positive. At 43.6x sales, investors are effectively paying a high multiple of current revenue for Viridian’s pipeline and future commercial potential rather than its present profitability.

Against that backdrop, Viridian’s P/S of 43.6x is described as expensive versus the US Biotechs industry average of 12.5x and also expensive against a peer average of 10x. The gap is even wider when set beside the estimated fair P/S ratio of 0.1x. This is a level the market could move toward if sentiment or expectations around the business were to change more in line with those benchmarks.

Result: Price-to-Sales of 43.6x (OVERVALUED)

However, the large full year net loss of US$281.93 million and the company’s dependence on successful thyroid eye disease approvals could quickly challenge any case for a premium P/S multiple.

Another View: DCF Signals Deep Undervaluation

If the P/S of 43.6x makes Viridian look expensive, our DCF model points in the opposite direction. On this view, the estimated future cash flow value sits at US$168.33 per share versus a US$30.25 price, suggesting a very large potential gap between price and implied value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Viridian Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 45 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

This mix of signals can feel conflicting. If you are interested, it makes sense to look through the latest data now and weigh both sides carefully, starting with 3 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Viridian has sparked your interest, it is worth widening your watchlist now so you are not relying on just one story for potential opportunity.

• Target potential mispricings by reviewing companies our screener flags as 45 high quality undervalued stocks backed by solid fundamentals and clear financial profiles.
• Prioritise resilience by scanning 76 resilient stocks with low risk scores that score well on stability and downside protection.
• Get ahead of the crowd by checking our screener containing 24 high quality undiscovered gems that have quality metrics yet still sit off most investors’ radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.